文献速递腹部CTMR

CT与MRI鉴别非弥漫型自身免疫性胰腺炎与胰腺导管腺癌的诊断性能比较

Comparison of diagnostic performance between CT and MRI in differentiating non-diffuse-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma.
PubMed 文献 · Eur Radiol · 2018-06-12

该研究纳入61例非弥漫型自身免疫性胰腺炎(AIP)和122例胰腺导管腺癌(PDA)患者,个体内比较动态增强CT与MRI(含MR胰胆管成像)的诊断性能。两名盲法阅片医师采用5分置信度评分,MRI的AUC(0.993-0.995)显著高于CT(0.953-0.976),且MRI对AIP和PDA的敏感度均高于CT。MRI在显示两种疾病的关键鉴别征象方面优于CT。

要点

  • MRI鉴别非弥漫型AIP与PDA的AUC(0.993-0.995)显著高于CT(0.953-0.976)。
  • MRI诊断AIP的敏感度为88.5-90.2%,CT为77-80.3%;诊断PDA的敏感度MRI为97.5-99.2%,CT为91.8-94.3%。
  • MRI显示AIP的多发胰腺肿块、延迟均匀强化及多发主胰管狭窄,以及PDA的离散胰腺肿块和主胰管狭窄,均显著优于CT。

核心结论

  • MRI鉴别非弥漫型AIP与PDA的诊断性能优于CT,归因于MRI在显示两种疾病关键鉴别征象方面优于CT。

研究设计与样本

  • 个体内比较研究,纳入61例非弥漫型AIP和122例PDA患者,均行动态增强CT和MRI(含MR胰胆管成像),两名盲法阅片医师独立采用5分置信度评分。

关键影像表现/征象

  • AIP在MRI上显示多发胰腺肿块、胰腺肿块延迟均匀强化及多发主胰管狭窄的频率显著高于CT(p≤0.008)。
  • PDA在MRI上显示离散胰腺肿块和主胰管狭窄的频率显著高于CT(p≤0.012)。

诊断标准与关键数值

  • MRI鉴别非弥漫型AIP与PDA的AUC为0.993-0.995,CT为0.953-0.976,两者差异显著(p≤0.035)。
  • MRI诊断AIP的敏感度为88.5-90.2%,CT为77-80.3%(p≤0.07,其中阅片者1的差异p=0.07,处于统计学边缘)。
  • MRI诊断PDA的敏感度为97.5-99.2%,CT为91.8-94.3%(p≤0.031)。

临床应用与阅片要点

  • 阅片时注意MRI对非弥漫型AIP的多发胰腺肿块、延迟均匀强化和多发主胰管狭窄的显示优于CT。
  • 阅片时注意MRI对PDA的离散胰腺肿块和主胰管狭窄的显示优于CT。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To intraindividually compare the diagnostic performance of CT and MRI in differentiating non-diffuse-type autoimmune pancreatitis (AIP) from pancreatic ductal adenocarcinoma (PDA).

METHODS: Sixty-one patients with non-diffuse-type AIP and 122 patients with PDA, who underwent dynamic contrast-enhanced CT and MRI with MR pancreatography, were included. Two blinded radiologists independently rated their confidence in differentiating the two diseases on a 5-point scale, and the diagnostic performances of CT and MRI were compared. The presence of key imaging features to differentiate AIP and PDA were compared between CT and MRI.

RESULTS: The area under the receiver operating characteristic curve was significantly greater on MRI (0.993-0.995) than on CT (0.953-0.976) for both raters (p≤0.035). The sensitivities of MRI were higher than those of CT for the diagnosis of AIP (88.5-90.2% vs. 77-80.3%, p≤0.07) and PDA (97.5-99.2% vs. 91.8-94.3%, p≤0.031) for both raters, although the difference for AIP was statistically marginal (p=0.07) for rater 1. In AIP, multiple pancreatic masses, delayed homogeneous enhancement of the pancreatic mass, and multiple main pancreatic duct (MPD) strictures were observed significantly more frequently using MRI than CT (p≤0.008). In PDA, discrete pancreatic mass and MPD stricture were observed significantly more frequently using MRI than CT (p≤0.012).

CONCLUSIONS: The diagnostic performance of MRI is better for differentiating non-diffuse-type AIP from PDA, which is due to the superiority of MRI over CT in demonstrating the key distinguishing features of both diseases.

KEY POINTS: • Imaging differential diagnosis of non-diffuse-type AIP and PDA is challenging. • MRI has better diagnostic performance than CT in differentiating non-diffuse-type AIP from PDA. • MRI is superior to CT in demonstrating key distinguishing features of non-diffuse-type AIP and PDA.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Lee S, Kim JH, Kim SY, et al. Comparison of diagnostic performance between CT and MRI in differentiating non-diffuse-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma. Eur Radiol. 2018. PMID: 29948075. doi:10.1007/s00330-018-5565-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。